FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3097326276> ?p ?o ?g. }

• W3097326276 endingPage "17" @default.
• W3097326276 startingPage "16" @default.
• W3097326276 abstract "BACKGROUND Patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), non-candidates for autologous stem-cell transplantation (ASCT), have few treatment options. Ibrutinib is an oral Bruton's tyrosine kinase inhibitor that has shown increased antitumor activity in patients with DLBCL of different subtype from germinal center B-cell like (non-GCB). In the present phase II clinical trial (NCT02692248), we investigated the efficacy and toxicity of the combination of Ibrutinib with the R-GEMOX-D regimen (rituximab, gemcitabine, oxaliplatin and dexamethasone), in patients with non- GCB DLBCL. METHODS We included patients with histological diagnosis of non-GCB DLBCL (according to Hans algorithm), with relapsed or refractory disease after at least 1 line of immunochemotherapy and non-candidates for ASCT. Patients received an induction treatment consisting of 6 (in case of complete remission [CR] after cycle 4) or 8 (in case of partial response [PR] or stable disease after cycle 4) cycles of R-GEMOX-D at standard doses every 2 weeks, in combination with ibrutinib (560 mg daily), followed by a maintenance treatment with ibrutinib for a maximum of 2 years. The primary objective was to evaluate the overall response rate (ORR) after 4 cycles, and the secondary objectives were: CR rate, progression-free survival (PFS), overall survival (OS) and toxicity. Analyses were performed in the intention to treat population (data cut-off 10th April 2020). RESULTS Sixty-four patients (59.4% male) were included between March 2016 and November 2018. Median age was 67 (25-84) years. Patients had received a median of 2 previous lines of treatment; 56.3% were refractory (&lt;PR) to the last regimen, whereas 43.7% had relapsed disease after a previous CR. Eleven (17.2%) patients had received a previous ASCT. IPI at study entry was 0-1, 2-3, and 4-5 in 9.4%, 67.2%, and 20.3% of patients, respectively (missing data in 2 patients). Of the 64 patients who started study treatment, 44 and 35 patients, respectively, were evaluated for response after 4th cycle and at the end of induction. Twenty-four (37%) patients started maintenance with ibrutinib, 7 of whom continue or have completed it. Causes of withdrawal from the trial (n=57) were progression (n=40), adverse event (n=6), transplantation (n=5), withdrawal of consent (n=3) and other causes (n=3). ORR and CR rate after 4th cycle were 53.2% and 35.9%, respectively. Patients with relapsed disease had significantly higher ORR (67.9% vs 41.7%, p=0.037) and CR rate (57.1% vs 19.4%, p=0.002) than patients with refractory disease. At the end of induction, ORR and CR rate were 35.9% and 29.7%, respectively. After a median follow-up of 22 months (range: 1 to 39 months), the estimated 2-year PFS and OS were 21% and 25%, respectively (Figure 1A and 1B), being significantly better in patients with relapsed disease (Figure 1C and 1D). In the multivariate analysis, status of lymphoma at study entry significantly influenced PFS (HR 0.45; 95% CI 0.25-0.82; p=0.009) and OS (HR 0.51; 95% CI 0.27-0.94; p=0.0031) independently from the IPI and the number of previous treatment lines. The most frequent adverse events (AE) (present in at least 20% of patients) were thrombocytopenia (67.2%), diarrhea (51.6%), neutropenia (46.9%), anemia (37.5%), fatigue (34.4%), nausea (29.7%) and paresthesia (20.3%). The most frequent grade 3-5 AE (present in at least 10% of patients) were thrombocytopenia (46.9%), neutropenia (35.9%), diarrhea (15.6%) and anemia (14.1%). Three patients presented a grade 5 AE, two of them related (aspergillosis and pneumonia, respectively) and one unrelated (heart failure). CONCLUSIONS The combination of ibrutinib with R-GEMOX-D as salvage therapy for patients with non-GCB DLBCL is associated with high response rates, especially in relapsed patients. The vast majority of refractory patients progress very early, so this regimen could be considered as a bridge to other consolidation therapies. Biological studies analyzing cell of origin by gene expression profiling, minimal residual disease and mutational spectrum are in progress. Disclosures Abrisqueta: Roche: Consultancy, Honoraria, Speakers Bureau; Celgene: Consultancy, Honoraria; Janssen: Consultancy, Honoraria, Speakers Bureau; AbbVie: Consultancy, Honoraria, Speakers Bureau. Giné:Janssen: Research Funding; Gilead: Research Funding; Roche: Research Funding. Grande:Janssen: Research Funding. Caballero:Roche: Other: travel; Gilead: Other: travel; Celgene: Membership on an entity's Board of Directors or advisory committees, Other: travel; Janssen: Membership on an entity's Board of Directors or advisory committees, Other: travel; BMS: Other: travel; Takeda: Other: travel; Kite: Membership on an entity's Board of Directors or advisory committees. Martin Garcia-Sancho:Roche, Celgene, Janssen, Servier, Gilead: Honoraria; Celgene, Eusa Pharma, Gilead, iQuone, Kyowa Kirin, Roche, Morphosys: Consultancy. OffLabel Disclosure: Off-label use of a new combination in the context of a clinical trial. New combination (Ibrutinib + R-GEMOX)" @default.
• W3097326276 created "2020-11-09" @default.
• W3097326276 creator A5004401859 @default.
• W3097326276 creator A5006074198 @default.
• W3097326276 creator A5007117385 @default.
• W3097326276 creator A5011343192 @default.
• W3097326276 creator A5017301854 @default.
• W3097326276 creator A5030696673 @default.
• W3097326276 creator A5038185841 @default.
• W3097326276 creator A5046620684 @default.
• W3097326276 creator A5052695708 @default.
• W3097326276 creator A5053894787 @default.
• W3097326276 creator A5056416386 @default.
• W3097326276 creator A5061223719 @default.
• W3097326276 creator A5065232101 @default.
• W3097326276 creator A5065778459 @default.
• W3097326276 creator A5071261900 @default.
• W3097326276 creator A5071331756 @default.
• W3097326276 creator A5075345973 @default.
• W3097326276 creator A5078238501 @default.
• W3097326276 date "2020-11-05" @default.
• W3097326276 modified "2023-10-18" @default.
• W3097326276 title "Ibrutinib in Combination with R-Gemox-D in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Phase II Clinical Trial of the Geltamo Group" @default.
• W3097326276 doi "https://doi.org/10.1182/blood-2020-140786" @default.
• W3097326276 hasPublicationYear "2020" @default.
• W3097326276 type Work @default.
• W3097326276 sameAs 3097326276 @default.
• W3097326276 citedByCount "0" @default.
• W3097326276 crossrefType "journal-article" @default.
• W3097326276 hasAuthorship W3097326276A5004401859 @default.
• W3097326276 hasAuthorship W3097326276A5006074198 @default.
• W3097326276 hasAuthorship W3097326276A5007117385 @default.
• W3097326276 hasAuthorship W3097326276A5011343192 @default.
• W3097326276 hasAuthorship W3097326276A5017301854 @default.
• W3097326276 hasAuthorship W3097326276A5030696673 @default.
• W3097326276 hasAuthorship W3097326276A5038185841 @default.
• W3097326276 hasAuthorship W3097326276A5046620684 @default.
• W3097326276 hasAuthorship W3097326276A5052695708 @default.
• W3097326276 hasAuthorship W3097326276A5053894787 @default.
• W3097326276 hasAuthorship W3097326276A5056416386 @default.
• W3097326276 hasAuthorship W3097326276A5061223719 @default.
• W3097326276 hasAuthorship W3097326276A5065232101 @default.
• W3097326276 hasAuthorship W3097326276A5065778459 @default.
• W3097326276 hasAuthorship W3097326276A5071261900 @default.
• W3097326276 hasAuthorship W3097326276A5071331756 @default.
• W3097326276 hasAuthorship W3097326276A5075345973 @default.
• W3097326276 hasAuthorship W3097326276A5078238501 @default.
• W3097326276 hasBestOaLocation W30973262761 @default.
• W3097326276 hasConcept C126322002 @default.
• W3097326276 hasConcept C141071460 @default.
• W3097326276 hasConcept C143998085 @default.
• W3097326276 hasConcept C2776694085 @default.
• W3097326276 hasConcept C2777063308 @default.
• W3097326276 hasConcept C2777938653 @default.
• W3097326276 hasConcept C2778461978 @default.
• W3097326276 hasConcept C2778559949 @default.
• W3097326276 hasConcept C2779338263 @default.
• W3097326276 hasConcept C2779878957 @default.
• W3097326276 hasConcept C2780653079 @default.
• W3097326276 hasConcept C2781413609 @default.
• W3097326276 hasConcept C2908647359 @default.
• W3097326276 hasConcept C31760486 @default.
• W3097326276 hasConcept C535046627 @default.
• W3097326276 hasConcept C71924100 @default.
• W3097326276 hasConcept C90924648 @default.
• W3097326276 hasConcept C99454951 @default.
• W3097326276 hasConceptScore W3097326276C126322002 @default.
• W3097326276 hasConceptScore W3097326276C141071460 @default.
• W3097326276 hasConceptScore W3097326276C143998085 @default.
• W3097326276 hasConceptScore W3097326276C2776694085 @default.
• W3097326276 hasConceptScore W3097326276C2777063308 @default.
• W3097326276 hasConceptScore W3097326276C2777938653 @default.
• W3097326276 hasConceptScore W3097326276C2778461978 @default.
• W3097326276 hasConceptScore W3097326276C2778559949 @default.
• W3097326276 hasConceptScore W3097326276C2779338263 @default.
• W3097326276 hasConceptScore W3097326276C2779878957 @default.
• W3097326276 hasConceptScore W3097326276C2780653079 @default.
• W3097326276 hasConceptScore W3097326276C2781413609 @default.
• W3097326276 hasConceptScore W3097326276C2908647359 @default.
• W3097326276 hasConceptScore W3097326276C31760486 @default.
• W3097326276 hasConceptScore W3097326276C535046627 @default.
• W3097326276 hasConceptScore W3097326276C71924100 @default.
• W3097326276 hasConceptScore W3097326276C90924648 @default.
• W3097326276 hasConceptScore W3097326276C99454951 @default.
• W3097326276 hasIssue "Supplement 1" @default.
• W3097326276 hasLocation W30973262761 @default.
• W3097326276 hasOpenAccess W3097326276 @default.
• W3097326276 hasPrimaryLocation W30973262761 @default.
• W3097326276 hasRelatedWork W1991224672 @default.
• W3097326276 hasRelatedWork W2134646407 @default.
• W3097326276 hasRelatedWork W2168450724 @default.
• W3097326276 hasRelatedWork W2623475747 @default.
• W3097326276 hasRelatedWork W2980014884 @default.
• W3097326276 hasRelatedWork W4210378956 @default.
• W3097326276 hasRelatedWork W4212971766 @default.
• W3097326276 hasRelatedWork W4310106470 @default.
• W3097326276 hasRelatedWork W4310108528 @default.
• W3097326276 hasRelatedWork W4310159650 @default.

• next